ArticleJournal of immunology (Baltimore, Md. : 1950)2014
Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Trial
- Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies.International journal of molecular sciences · 2025Review
- Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects.Pharmacological reports : PR · 2024Review
- CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.Acta neuropathologica communications · 2022Article
- Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Frontiers in immunology · 2020Review
- Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.Brain : a journal of neurology · 2019Article
- B cell checkpoints in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2019Review
- The role of B cells in multiple sclerosis: Current and future therapies.Cellular immunology · 2019Review
- Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?Auto- immunity highlights · 2018Review
- B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Therapeutic advances in neurological disorders · 2018Review
- A lifetime aging study of human CD19 transgenic mice.Transgenic research · 2017Article
- Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.Journal of clinical medicine · 2016Review
- Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.Current treatment options in neurology · 2016Article
- B cells and progressive multifocal leukoencephalopathy: search for the missing link.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Plasma cells and the autoreactive Abs they produce are suspected to contribute to the pathogenesis of multiple sclerosis, but recent attempts to target these components of humoral immunity have failed. MEDI551, an anti-CD19 Ab that depletes mature B cells including plasma cells may offer a compelling alternative that reduces pathogenic adaptive immune responses while sparing regulatory mechanisms. Indeed, our data demonstrate that a single dose of MEDI551, given before or during ongoing experimental autoimmune encephalomyelitis, disrupts development of the disease. Leukocyte infiltration into the spinal cord is significantly reduced, as well as short-lived and long-lived autoreactive CD138(+) plasma cells in the spleen and bone marrow, respectively. In addition, potentially protective CD1d(hi)CD5(+) regulatory B cells show resistance to depletion, and myelin-specific Foxp3(+) regulatory T cells are expanded. Taken together, these results demonstrate that MEDI551 disrupts experimental autoimmune encephalomyelitis by inhibiting multiple proinflammatory components whereas preserving regulatory populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.